
    
      This is a randomized, double-blind, placebo-controlled, single centre Phase I study.

      Eighteen (18) subjects are planned to be randomised at 1 site across the 2 parts of the study
      as follows:

        -  Cohort 1: 680 mg/day

        -  Cohort 2: 6800 mg/day
    
  